News
INmune Bio's XPro shows promise in early AD despite missed endpoints. Click here to find out why I rate INMB stock is a Hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results